$HRTX

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 4, 2025, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 5, 2025, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates — source image
Decision brief

The 30-second read

$HRTXNeutralLow
01

Why it matters

The earnings report aligns with analyst expectations, suggesting no immediate revaluation. Investors should consider broader industry trends and company-specific news for a comprehensive view.

02

Market read

While the earnings are in line with expectations, the impact on stock price is expected to be minimal, given the neutral surprise factor.

03

What to watch

Potential upcoming pipeline developments or regulatory decisions could influence future performance beyond current earnings.

Timing: short-term (next few days)

Background

Heron Therapeutics is a biotech company focusing on innovative therapies. The Q3 2025 earnings are a key indicator of its current financial health.

Company-level read

Ticker impact

$HRTXNeutralMedium confidence
Context

Heron Therapeutics Q3 2025 earnings report and comparison with Wall Street estimates.

Expected impact

Limited immediate price movement; potential for slight volatility depending on investor interpretation.

Evidence & confidence

The earnings figures are in line with expectations, suggesting no significant surprise. Market reactions are likely to be subdued, but minor volatility could occur based on investor sentiment.

Market effects

The pharmaceutical/biotech sector may experience minimal movement, as Heron Therapeutics' results are in line with expectations.

Limited regional impact; primarily affects investors and stakeholders in the US market.

Low; the company's performance is unlikely to influence global markets significantly.

Counterpoint

Some investors might interpret the results as a sign of underlying stability, potentially supporting a cautious bullish stance.

Key entities

  • Heron Therapeutics

    A biotechnology company specializing in innovative therapies.

  • Wall Street analysts

    Financial analysts providing earnings estimates and market forecasts.

Related articles

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-yea

$NVDAMed

Nvidia teams up with Wall Street asset managers on $500 billion AI infrastructure push

CNBC reports Nvidia is working with Apollo, Blackstone, BlackRock’s Global Infrastructure Partners, Brookfield, Goldman Sachs and KKR on a planned $500 billion financing push for AI infrastructure, citing an unnamed source. An announcement could come as soon as Monday, according to the report. The effort would help customers finance Nvidia GPUs and data centers, including power capacity needs.

$ARTWMed

Art's-Way Manufacturing Co.: Art's Way Announces Significant Increase in Backlog Following Award of Major Modular Building Projects

Art's-Way Manufacturing Co. (Nasdaq:ARTW) said its Modular Buildings segment backlog rose to over $19.0 million after winning major modular building projects. The company cited a prior $1.3 million backlog in its May 31, 2026 10-Q. It expects fulfillment by end of fiscal 2027, subject to schedules and milestones, with margins generally consistent with historical performance.